DAWN Overview

Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. It partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor. OJEMDA is used for the treatment of patients over six months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Its pipeline product candidates include DAY301 and Emi-Le (emiltatug ledadotin). DAY301 is a novel Antibody Drug Conjugate, or ADC, targeting protein-tyrosine kinase 7, or PTK7. Emi-Le (emiltatug ledadotin) is a novel antibody drug conjugate (ADC) targeting the B7-H4 protein in clinical development to treat the rare cancer adenoid cystic carcinoma (ACC).

Wall Street analysts forecast DAWN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DAWN is22.29 USD with a low forecast of 16.00 USD and a high forecast of 29.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Day One Biopharmaceuticals Inc revenue for the last quarter amounts to 53.72M USD, increased 83.92

Day One Biopharmaceuticals Inc. EPS for the last quarter amounts to -0.21 USD, decreased -67.19

Day One Biopharmaceuticals Inc (DAWN) has 178 emplpoyees as of March 12 2026.

Today DAWN has the market capitalization of 2.20B USD.